MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202611107873 A) filed by Maharishi Markandeshwar Deemed To Be University on September 08, 2026, for Novel Chitosan/Graphene Oxide Nanocomposite Formulation Of Repaglinide.
Inventors include Dr. Renu Saharan; Prof. Dr. Sarvesh Paliwal; and Dr. Suresh Kumar.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: The present invention relates to a novel chitosan/graphene oxide nanocomposite hydrogel bead formulation of Repaglinide for controlled and sustained oral drug delivery in the management of diabetes mellitus. The formulation comprises Repaglinide encapsulated within a cross-linked matrix of chitosan and graphene oxide, providing improved drug entrapment, structural stability and controlled release. The nanocomposite hydrogel beads are prepared by ionotropic gelation and optimized using a Box-Behnken Design. The optimized formulation containing 60 mg chitosan, 20 mg graphene oxide and 20 mg Repaglinide exhibits an entrapment efficiency of 92.95 ± 0.129% and drug loading efficiency of 18.34 ± 0.047%. The formulation demonstrates pH-dependent swelling and a biphasic sustained drug-release profile extending up to 20 hours, with 86.96% cumulative release over 24 hours. In vivo evaluation further demonstrates effective reduction of blood glucose levels.
Disclaimer: Curated by HT Syndication.
